MedTrace Logo

Comparison of 2 Low Molecular Weight Heparin as a Thromboprophylaxis Postpartum

NCT01588171 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 7020

Last updated 2025-11-21

No results posted yet for this study

Summary

The use of a new generation low molecular weight heparin (Bemiparin)and the well known LMWH (Enoxaparin) after Caesarean sections and vaginal deliveries in a risky group patients for venous thrombosis.

Conditions

  • Venous Thromboembolic Diseases

Interventions

DRUG

Bemiparin

Bemiparin sodium 3,500 IU anti Xa/0.3 ml solution for injection in pre-filled syringe will be provided for each patient in Bemiparin group; subcutaneously 6 hours after delivery(vaginal and Caesarean)and then daily for up to 7 days.

DRUG

Enoxaparin

Enoxaparin sodium 40mg (equivalent to 4,000 IU anti-Xa activity) in 0.4ml water for injection will be administered subcutaneously 6 hours after the delivery( vaginal or abdominal)then daily up to 7 days post partum, for Enoxaparin group of patients.

Sponsors & Collaborators

  • Hawler Medical University

    lead OTHER

Principal Investigators

  • Shahla K. Alalaf, Ass.Prof · Hawler Medical University

  • Rojan K. Jawad, High Diploma · Hawler Medical University

  • Parez R. Muhammad, High Diploma · Hawler Medical University

  • Mahabad S. Ali, High Diploma · Hawler ministry of Health, Directorate of Health

  • Namir G. Al Tawil, Professor · Hawler Medical University

Study Design

Allocation
NON_RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
15 Years
Max Age
48 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-05-31
Primary Completion
2013-10-31
Completion
2013-11-30

Countries

  • Iraq

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01588171 on ClinicalTrials.gov